38.06
price down icon4.32%   -1.72
after-market Handel nachbörslich: 38.10 0.04 +0.11%
loading
Schlusskurs vom Vortag:
$39.78
Offen:
$40
24-Stunden-Volumen:
616.60K
Relative Volume:
0.43
Marktkapitalisierung:
$278.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-3.3801
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
+31.56%
1M Leistung:
+90.30%
6M Leistung:
+103.75%
1J Leistung:
-92.70%
1-Tages-Spanne:
Value
$36.77
$40.41
1-Wochen-Bereich:
Value
$29.74
$42.96
52-Wochen-Spanne:
Value
$7.31
$549.12

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name
Firmenname
Tonix Pharmaceuticals Holding Corp
Name
Telefon
212-980-9155
Name
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Name
Mitarbeiter
81
Name
Twitter
@TONIXPharma
Name
Nächster Verdiensttermin
2025-03-17
Name
Neueste SEC-Einreichungen
Name
TNXP's Discussions on Twitter

Vergleichen Sie TNXP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TNXP
Tonix Pharmaceuticals Holding Corp
38.06 270.94M 0 -121.02M -114.09M -11.26
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-04-18 Eingeleitet Noble Capital Markets Outperform
2019-04-18 Hochstufung ROTH Capital Neutral → Buy
2017-08-18 Hochstufung ROTH Capital Neutral → Buy
2016-09-07 Herabstufung ROTH Capital Buy → Neutral
2016-02-17 Bestätigt Oppenheimer Outperform
2015-11-04 Eingeleitet Cantor Fitzgerald Buy
2015-06-12 Eingeleitet Oppenheimer Outperform
2015-02-17 Bestätigt ROTH Capital Buy
2014-09-29 Bestätigt ROTH Capital Buy
Alle ansehen

Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten

pulisher
Jun 01, 2025

Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Defense World

Jun 01, 2025
pulisher
May 30, 2025

Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet (NASDAQ:TNXP) - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - Revista ADVFN

May 29, 2025
pulisher
May 29, 2025

How the (TNXP) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Tonix Pharmaceuticals (TNXP) Stock Surges Over 10%: What's Fueling the Rally and What's Next? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 28, 2025

What's Going On With Tonix Pharmaceuticals Stock? - Benzinga

May 28, 2025
pulisher
May 28, 2025

TNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia… - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

TNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia - Research Tree

May 28, 2025
pulisher
May 23, 2025

Tonix Pharmaceuticals CEO Highlights Strategic Vision at Healthcare Showcase - citybuzz -

May 23, 2025
pulisher
May 22, 2025

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - GlobeNewswire

May 22, 2025
pulisher
May 21, 2025

Tonix begins trial for stress reaction treatment By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

Tonix begins trial for stress reaction treatment - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 O - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals (TNXP) Commences Phase 2 Trial for Stress Disorder Treatment | TNXP Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Tonix Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

DoD Backs Revolutionary Acute Stress Treatment: First Patient Dosed in $3M Phase 2 Trial - Stock Titan

May 21, 2025
pulisher
May 16, 2025

Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results - Benzinga

May 16, 2025
pulisher
May 15, 2025

Stocks To Watch: Tonix Pharmaceuticals Sees RS Rating Jump To 89 - inkl

May 15, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Recruits Seasoned Industry Atty As GC - Law360

May 14, 2025
pulisher
May 14, 2025

Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive - Investing.com India

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Names Joseph Hand as General Counsel and Executive Vice President of Operations - citybuzz -

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Appoints Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - citybiz

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EV - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EVP of Operations | TNXP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tonix Pharma Appoints New General Counsel and EVP - TipRanks

May 14, 2025
pulisher
May 14, 2025

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Tonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Tonix Pharma earnings beat by $22.84, revenue fell short of estimates - Investing.com

May 12, 2025
pulisher
May 12, 2025

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights | TNXP Stock News - GuruFocus

May 12, 2025
pulisher
May 09, 2025

Tonix Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Tonix Pharmaceuticals reports annual meeting results - Investing.com Australia

May 09, 2025
pulisher
May 08, 2025

Tonix showcases promising gastric cancer data at AACR Conference - Proactive financial news

May 08, 2025
pulisher
May 08, 2025

(TNXP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Tonix Pharma drops after Q4 revenue miss - MSN

May 07, 2025
pulisher
May 06, 2025

Tonix Pharmaceuticals: Looking Past FDA Approval To Challenging Commercial Opportunity - Seeking Alpha

May 06, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700 - citybuzz -

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharma Unveils Promising Cancer Treatment Data - TipRanks

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals (TNXP) Showcases Promising Cancer Research at AACR 2025 | TNXP Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Canc - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Tonix Pharmaceuticals and Makana partner to advance research with Anti-Rejection therapy - Proactive Investors

Apr 29, 2025
pulisher
Apr 29, 2025

Groundbreaking Cancer Therapy Shows Promise: Tonix's New Combination Treatment Activates Cancer-Killing Cells - Stock Titan

Apr 29, 2025
pulisher
Apr 28, 2025

Tonix Pharmaceuticals culls cocaine intoxication trial amid enrollment woes - Fierce Biotech

Apr 28, 2025
pulisher
Apr 25, 2025

Tonix Pharmaceuticals Holding CorpDiscontinued Enrollment And Terminated Phase 2 Catalyst StudySEC Filing - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data - citybuzz -

Apr 25, 2025

Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Kapitalisierung:     |  Volumen (24h):